• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• antibody–drug conjugate
• sacituzumab govitecan
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus nab-paclitaxel
• atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
• atezolizumab plus paclitaxel
• durvalumab based treatment
• durvalumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus SoC
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib
• talazoparib
• veliparib plus paclitaxel plus carboplatin

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs non active control
• vs placebo

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only